Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 1, 2005, Pages 63-68

  Bergshoeff, Alina S ^a   Fraaij, Pieter L ^b   Ndagijimana, Jennifer ^c   Verweel, Gwenda ^b   Hartwig, Nico G ^b   Niehues, Tim ^c   De Groot, Ronald ^b   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Children; Drug interaction; Efavirenz; Lopinavir; Pharmacokinetics; Ritonavir

Indexed keywords

EFAVIRENZ; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; STEADY STATE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; OXAZINES; PYRIMIDINONES; RITONAVIR; SAFETY;

EID: 18144412382     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000155203.89350.85     Document Type: Article

References (37)

1. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis. 2002;2:93-102.
2. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528.
3. Anonymous. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at: www.aidsinfo.nih.gov/guidelines/pediatric. Accessed November 17, 2003.
4. Sharland M, Blanche S, Castelli G, et al. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med. 2004;5(Suppl 2):61-86.
5. Seminari E, Maggiolo F, Villani P, et al. Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors. J Acquir Immune Defic Syndr. 1999;22:453-460.
6. Piketty C, Race E, Castiel P, et al. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS. 1999;13:F71-F77.
7. Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 2001;345:398-407.
8. Joly V, Descamps D, Yeni P. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens. AIDS Rev. 2002;4:128-139.
9. Cvetkovic R, Goa K. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63:769-802.
10. Viramune [summary of product characteristics]. Ingelheim am Rhein, Germany: Boehringer Ingelheim International GmbH; 1999.
11. Stocrin [summary of product characteristics]. Hertfordshire, UK: Merck Sharp & Dohme, Ltd.; 2002.
12. Bertz R, Foit C, Burt D, et al. Assessment of the effect of nevirapine on the pharmacokinetics of lopinavir/ritonavir (Kaletra (R) after multiple dosing in HIV-infected adults. Paper presented at: XIVth International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract TuPeB4565. 2002.
13. Bertz R, Lam W, Hsu A, et al. Assessment of the Pharmacokinetic interaction between ABT-378/ritonavir (ABT-378/r) and efavirenz (EFV) in healthy volunteers and in HIV+ subjects. Paper presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto, Canada. Abstract 424. 2000.
14. Hsu A, Bertz R, Lam W, et al. Assessment of Pharmacokinetic interactions between Kaletra (lopinavir/ritonavir or ABT-378/r) and nevirapine in pediatric subjects. Paper presented at: 5th International Congress on Drug Therapy in HIV Infection; October 2000; Glasgow, UK. Abstract 440, poster. 2000.
15. Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22:216-224.
16. Fraaij PL, Neubert J, Bergshoeff AS, et al. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children. Antivir Ther. 2004;9:297-299.
17. Kaletra [summary of product characteristics]. Chicago, IL: Abbott; 2000.
18. Droste JAH, Verweij-van Wissen CPWGM, Burger D, et al. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxyraetabolite M8 and nevirapine in human plasma by reversed phase high performance liquid chromatography. Ther Drug Monit. 2003;25:393-399.
19. Aarnoutse RE, Grintjes KJ, Telgt DS, et al. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther. 2002;71:57-67.
20. Gibaldi M. Compartmental and noncompartmental pharmacokinetics. In: Biopharmaceutics and Clinical Pharmacokinetics. Philadelphia, London: Lea & Febiger; 1991:14-23.
21. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2003;47:350-359.
22. Villani P, Regazzi MB, Castelli F, et al. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol. 1999;48:712-715.
23. Optimising TDM in HIV clinical care: a practical guide to performing therapeutic drug monitoring (TDM) for antiretroviral agents. Available at: http://www.HIVpharmacology.com. Accessed May 24, 2004.
24. Molla A, Vasavanonda S, Kumar G, et al. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology. 1998;250:255-262.
25. Kempf DJ, Isaacson JD, King MS, et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther. 2002;7:165-174.
26. Masquelier B, Breilh D, Neau D, et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2002;46:2926-2932.
27. Mouly S, Lown KS, Kornhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther. 2002;72:1-9.
28. Profit L, Eagling VA, Back DJ. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS. 1999;13:1623-1627.
29. Drewe J, Gutmann H, Fricker G, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 1999;57:1147-1152.
30. Olson DP, Scadden DT, D'Aquila RT, et al. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS. 2002;16:1743-1747.
31. Garraffo R, Durant J, Chaillou S, et al. in vitro and in vivo protease inhibitors (PI) kinetics in human cells expressing or not MDR1: role of ritonavir (RI) in intracellular PI accumulation. Paper presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto, Canada. Abstract 1167. 2000.
32. Guiard-Schmid JB, Poirier JM, Meynard JL, et al. High variability of plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother. 2003;47:986-990.
33. Wandel C, Witte JS, Hall JM, et al. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther. 2000;68:82-91.
34. Ball SE, Scatina J, Kao J, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther. 1999;66:288-294.
35. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189-199.
36. Schaeffeler E, Eichelbaum M, Brinkmann U, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet. 2001;358:383-384.
37. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42:59-98.